BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treat Rev 2016;43:74-82. [PMID: 26827695 DOI: 10.1016/j.ctrv.2015.12.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Finelli A, Beer TM, Chowdhury S, Evans CP, Fizazi K, Higano CS, Kim J, Martin L, Saad F, Saarela O. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. JAMA Netw Open 2021;4:e2112426. [PMID: 34129025 DOI: 10.1001/jamanetworkopen.2021.12426] [Reference Citation Analysis]
2 Shih WJ, Lin Y. Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Stat Med 2018;37:687-709. [PMID: 29205435 DOI: 10.1002/sim.7562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Kim RS, Goossens N, Hoshida Y. Use of big data in drug development for precision medicine. Expert Rev Precis Med Drug Dev 2016;1:245-53. [PMID: 27430024 DOI: 10.1080/23808993.2016.1174062] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
4 Ou FS, Le-Rademacher JG, Ballman KV, Adjei AA, Mandrekar SJ. Guidelines for Statistical Reporting in Medical Journals. J Thorac Oncol 2020;15:1722-6. [PMID: 32858236 DOI: 10.1016/j.jtho.2020.08.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lévy V. Of some innovations in clinical trial design in hematology and oncology. Therapie 2021:S0040-5957(21)00245-6. [PMID: 34922739 DOI: 10.1016/j.therap.2021.10.011] [Reference Citation Analysis]
6 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials 2020;21:528. [PMID: 32546273 DOI: 10.1186/s13063-020-04334-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
7 van Dam PJ, Daelemans S, Ross E, Waumans Y, Van Laere S, Latacz E, Van Steen R, De Pooter C, Kockx M, Dirix L, Vermeulen PB. Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. Semin Cancer Biol 2018;52:86-93. [PMID: 29355613 DOI: 10.1016/j.semcancer.2018.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
8 Zhang L, Liang Y, Li S, Zeng F, Meng Y, Chen Z, Liu S, Tao Y, Yu F. The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis. Mol Cancer 2019;18:36. [PMID: 30849971 DOI: 10.1186/s12943-019-0989-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
9 Weiss JA, Nicklawsky A, Kagihara JA, Gao D, Fisher C, Elias A, Borges VF, Kabos P, Davis SL, Leong S, Eckhardt SG, Diamond JR. Clinical outcomes of breast cancer patients treated in phase I clinical trials at University of Colorado Cancer Center. Cancer Med 2020;9:8801-8. [PMID: 33063469 DOI: 10.1002/cam4.3487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Lam M, Loree JM, Pereira AAL, Chun YS, Kopetz S. Accelerating Therapeutic Development through Innovative Trial Design in Colorectal Cancer. Curr Treat Options Oncol 2018;19:11. [PMID: 29488033 DOI: 10.1007/s11864-018-0524-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
11 Oliveres H, Pineda E, Maurel J. MET inhibitors in cancer: pitfalls and challenges. Expert Opin Investig Drugs 2020;29:73-85. [PMID: 31783719 DOI: 10.1080/13543784.2020.1699532] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
12 Morita S, Müller P. Bayesian population finding with biomarkers in a randomized clinical trial. Biometrics 2017;73:1355-65. [PMID: 28257141 DOI: 10.1111/biom.12677] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
13 Morita S, Müller P, Abe H. A semiparametric Bayesian approach to population finding with time-to-event and toxicity data in a randomized clinical trial. Biometrics 2021;77:634-48. [PMID: 32339262 DOI: 10.1111/biom.13289] [Reference Citation Analysis]
14 Renfro LA, Sargent DJ. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples. Ann Oncol 2017;28:34-43. [PMID: 28177494 DOI: 10.1093/annonc/mdw413] [Cited by in Crossref: 130] [Cited by in F6Publishing: 110] [Article Influence: 32.5] [Reference Citation Analysis]
15 Sánchez NS, Mills GB, Mills Shaw KR. Precision oncology: neither a silver bullet nor a dream. Pharmacogenomics 2017;18:1525-39. [PMID: 29061079 DOI: 10.2217/pgs-2017-0094] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Yin G, Yang Z, Odani M, Fukimbara S. Bayesian Hierarchical Modeling and Biomarker Cutoff Identification in Basket Trials. Statistics in Biopharmaceutical Research 2021;13:248-58. [DOI: 10.1080/19466315.2020.1811146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Stoppe C, Wendt S, Mehta NM, Compher C, Preiser JC, Heyland DK, Kristof AS. Biomarkers in critical care nutrition. Crit Care 2020;24:499. [PMID: 32787899 DOI: 10.1186/s13054-020-03208-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
18 Hu C, Dignam JJ. Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. JCO Precis Oncol 2019;3:PO. [PMID: 32923854 DOI: 10.1200/PO.19.00086] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Zhao W, Ma W, Wang F, Hu F. Incorporating covariates information in adaptive clinical trials for precision medicine. Pharm Stat 2021. [PMID: 34369053 DOI: 10.1002/pst.2160] [Reference Citation Analysis]
20 Diao G, Dong J, Zeng D, Ke C, Rong A, Ibrahim JG. Biomarker threshold adaptive designs for survival endpoints. J Biopharm Stat 2018;28:1038-54. [PMID: 29436940 DOI: 10.1080/10543406.2018.1434191] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Lin Y, Shih WJ, Lu SE. Two-stage enrichment clinical trial design with adjustment for misclassification in predictive biomarkers. Stat Med 2019;38:5445-69. [PMID: 31621944 DOI: 10.1002/sim.8370] [Reference Citation Analysis]
22 García-Albéniz X, Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02). Oncologist 2019;24:e1115-22. [PMID: 31235483 DOI: 10.1634/theoncologist.2018-0728] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
23 Morfouace M, Hewitt SM, Salgado R, Hartmann K, Litiere S, Tejpar S, Golfinopoulos V, Lively T, Thurin M, Conley B, Lacombe D. A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. Semin Cancer Biol 2018;52:158-65. [PMID: 29307568 DOI: 10.1016/j.semcancer.2018.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Antoniou M, Kolamunnage-Dona R, Jorgensen AL. Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review. J Pers Med 2017;7:E1. [PMID: 28125057 DOI: 10.3390/jpm7010001] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 4.4] [Reference Citation Analysis]
25 Wulfkuhle JD, Spira A, Edmiston KH, Petricoin EF. Innovations in Clinical Trial Design in the Era of Molecular Profiling. In: Espina V, editor. Molecular Profiling. New York: Springer; 2017. pp. 19-36. [DOI: 10.1007/978-1-4939-6990-6_2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
26 Breitenstein MK, Liu H, Maxwell KN, Pathak J, Zhang R. Electronic Health Record Phenotypes for Precision Medicine: Perspectives and Caveats From Treatment of Breast Cancer at a Single Institution. Clin Transl Sci 2018;11:85-92. [PMID: 29084368 DOI: 10.1111/cts.12514] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Gershenson DM, Gourley C, Paul J. MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype. J Clin Oncol 2020;38:3731-4. [PMID: 32897828 DOI: 10.1200/JCO.20.02190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Superchi C, Brion Bouvier F, Gerardi C, Carmona M, San Miguel L, Sánchez-Gómez LM, Imaz-Iglesia I, Garcia P, Demotes J, Banzi R, Porcher R; PERMIT Group. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open 2022;12:e052926. [PMID: 35523482 DOI: 10.1136/bmjopen-2021-052926] [Reference Citation Analysis]
29 Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, Mander AP, Weir CJ, Koenig F, Walton MK, Nicholl JP, Coates E, Biggs K, Hamasaki T, Proschan MA, Scott JA, Ando Y, Hind D, Altman DG; ACE Consensus Group. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 2020;369:m115. [PMID: 32554564 DOI: 10.1136/bmj.m115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
30 Meyer EL, Mesenbrink P, Dunger-baldauf C, Fülle H, Glimm E, Li Y, Posch M, König F. The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. Clinical Therapeutics 2020;42:1330-60. [DOI: 10.1016/j.clinthera.2020.05.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
31 Torres-Saavedra PA, Winter KA. An Overview of Phase 2 Clinical Trial Designs. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02611-0. [PMID: 34363901 DOI: 10.1016/j.ijrobp.2021.07.1700] [Reference Citation Analysis]
32 Janiaud P, Serghiou S, Ioannidis JP. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Cancer Treatment Reviews 2019;73:20-30. [DOI: 10.1016/j.ctrv.2018.12.003] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 17.3] [Reference Citation Analysis]
33 Tsimberidou AM, Müller P, Ji Y. Innovative trial design in precision oncology. Seminars in Cancer Biology 2020. [DOI: 10.1016/j.semcancer.2020.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Liu M, Li Q, Lin J, Lin Y, Hoffman E. Innovative trial designs and analyses for vaccine clinical development. Contemp Clin Trials 2021;100:106225. [PMID: 33227451 DOI: 10.1016/j.cct.2020.106225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Parmar MK, Sydes MR, Cafferty FH, Choodari-Oskooei B, Langley RE, Brown L, Phillips PP, Spears MR, Rowley S, Kaplan R, James ND, Maughan T, Paton N, Royston PJ. Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. Clin Trials 2017;14:451-61. [PMID: 28830236 DOI: 10.1177/1740774517725697] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]